

01-10-2018 08:53 AM CET - Health & Medicine

Print

Enable Injections Names Jeannie Joughin, Ph.D. Executive Vice President and Chief Commercial Officer

Press release from: **KOGS Communication**
PR Agency: KOGS Communication LLC



Dr. Jeannie Joughin named Enable Injections' Executive Vice President and Chief Commercial Officer

Drug Delivery Partnerships - Experience Cutting Edge Tech

Accelerate Drugs to Market. PGA National Resort & Spa. Jan 22-24
lifesciences.knect365.com/Register/Now

CINCINNATI, OH—January 9, 2018—Enable Injections, Inc., developer of the advanced enFuse™ large-volume wearable injectors (LVWI) platform for subcutaneous delivery of biologics, has named Dr. Jeannette "Jeannie" Joughin Executive Vice President and Chief Commercial Officer.

A global pharmaceutical executive and long-time champion of a patient-focused approach to treatment, Dr. Joughin joined the company as Vice President of Corporate Development in 2015. In her new role she will support the CEO and Board with investment strategy and remains responsible for business development, strategic pharma partnerships, alliance management, as well as aiding in selection and prioritization of Enable Injections' global portfolio.

"Jeannie has exceptional experience and a proven track record of developing mutually-beneficial partnerships with pharmaceutical companies who share our passion for radically improving the patient infusion experience," said Michael D. Hooven, Enable Injections' President and CEO. "Today we are recognizing her leadership in helping to drive the next phase of growth for Enable Injections."

Prior to joining Enable Injections, Dr. Joughin was Vice President, Business Development at drug maker CSL Behring, with global responsibility. The Australian native also served as Marketing Manager at Mayne Pharma, as General Manager of Medimark International, and held clinical and commercial roles at Bristol-Myers Squibb.

#

About Enable Injections, Inc.

Founded by medical device industry veterans, Cincinnati, OH-based Enable Injections develops and manufactures wearable devices that allow easy, comfortable patient self-administration of large volume/high viscosity drugs in doses from 4 ml to 50 ml. The Enable body-worn enFuse™ drug delivery platform utilizes any standard container closure system, including syringes or vials; automatically warms and can automatically mix lyophilized solutions. Enable's devices are available for pharmaceutical and biotechnology industry investigational use. For more information please visit www.enableinjections.com and follow us on [www.twitter.com/EnableInjection](https://twitter.com/EnableInjection).

2863 E. Sharon Rd.
Cincinnati OH 45241

This release was published on openPR.

Search GO

More Releases from KOGS Communication
No further reports available

Comments about openPR

OpenPR ist the nicest and most clearly laid out PR platform I have seen to this day. The press releases are displayed very nicely and clearly and without any unnecessary frills. The updates are fast and the finished release looks appealing and is clearly legible. Even with 16 years of experience one discovers new things from time to time. Congratulations!

Gabriele Ketterl, Director Marketing & PR, Menads

Your Press Releases on Google News

openPR.de

1 | Drug Delivery Conference - New Profitable Partnerships

World's Largest Drug Delivery Meeting to Accelerate Drugs to Market. Jan 22-24

lifesciences.knect365.com

2 | Download PDF

To View PDF, Download Here

DocToPDF

From The Web Sponsored Links

Try Not To Gasp When You See What Dog's Wife Looks Like Now
Miss Penny Stocks

Bitcoin is Dead - This Will Make Investors Rich in 2018
Bonner and Partners Subscription

If You Have Thinning Hair, Watch This Now
JuveTress

This Photographer Snuck 28 Illegal Photos Out Of North Korea
StandardNews

by Taboola